Hubro Bioscience

Hubro Therapeutics is a clinical-stage biotechnology company based in Oslo, Norway, specializing in the development of novel immunotherapies for cancer. The company focuses on off-the-shelf peptide vaccines that target common frameshift mutations found in microsatellite instability-high (MSI-H) tumors. Its lead program, HU-101, is designed to elicit a T-cell response against neoantigens derived from mutations in the Transforming growth factor beta receptor type 2 (TGFBR2) gene. By targeting these highly immunogenic and tumor-specific antigens, Hubro aims to provide effective treatments for patients with colorectal, gastric, and other MSI-H cancers. The company's technology platform is built upon decades of research into frameshift mutations and their role in tumor immunology. Hubro is currently advancing its lead candidate through Phase 1/2 clinical trials to demonstrate safety and immunogenicity in patients with advanced disease.